ChemicalBook > Product Catalog >Biochemical Engineering >Biochemical Reagents >Agonist Inhibitors >CEP-32496

CEP-32496

CEP-32496 Suppliers list
Company Name: China Langchem Inc.  
Tel: 0086-21-58956006
Email:
Company Name: MedChemexpress LLC  
Tel: 021-58955995
Email: sales@medchemexpress.cn
Company Name: AdooQ BioScience, LLC   
Tel: +1 (866) 930-6790
Email: info@adooq.com
Company Name: CEG Chemical Science&Technology Co., Ltd.  
Tel: Mobile:13665161512
Email:
Company Name: LETOPHARM LIMITED  
Tel: +86-21-5821 5861
Email: sales@letopharm.com
CEP-32496 Basic information
Product Name:CEP-32496
Synonyms:CEP-32496;1-(3-(6,7-diMethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-Methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride;CEP 32496 hydrochloride;CEP-32496 (hydrochloride);CEP32496 hydrochloride;CEP-32496 HCl salt;1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxaz;N-[3-[(6,7-Dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[5-(2,2,2-trifluoro-1,1-dimethylethyl)-3-isoxazolyl]urea hydrochloride
CAS:1227678-26-3
MF:C24H23ClF3N5O5
MW:553.9181296
EINECS:
Product Categories:
Mol File:1227678-26-3.mol
CEP-32496 Structure
CEP-32496 Chemical Properties
storage temp. Store at -20°C
solubility Soluble in DMSO
form Powder
Safety Information
MSDS Information
CEP-32496 Usage And Synthesis
UsesCEP 32496 is an orally active BRAFV600E inhibitor with selective cellular and in vivo antitumor activity.
in vivo

Oral administration of Agerafenib (CEP-32496) to Colo-205 tumor xenograft-bearing mice results in significant inhibition of pMEK in tumor cell lysates. For instance, a single 30 mg/kg (po) dose of Agerafenib (CEP-32496) leads to a 50 and 75% inhibition of normalized pMEK in tumor lysates at the 2 and 6 h postdose time point, respectively (p<0.03), while a 55 mg/kg (po) dose resulted in a 75% to 57% (p<0.03) inhibition of pMEK at 2 through 10 h post administration, with normalization to baseline by 24 h. Agerafenib (CEP-32496) exhibits an exceptional PK profile in mouse, dog, and cynomolgus monkey. Administration of Agerafenib (CEP-32496) to beagle dogs (single dose of 1 mg/kg iv and 10 mg/kg po) results in low clearance (CL=5.0 (mL/min)/kg) and excellent bioavailability (%F=100). Similarly, in cynomolgus monkey, the administration of Agerafenib (CEP-32496) (single dose of 1 mg/kg iv and 10 mg/kg po) leads to high oral exposure due to low clearance (CL=6.7 mL/min/kg) and excellent bioavailability (%F=100)[1].

targetwild-type BRAF
IC 50BRafV600E: 14 nM (Kd); Braf: 36 nM (Kd); CRAF: 39 nM (Kd); c-Kit: 2 nM (Kd); Ret: 2 nM (Kd); LCK: 2 nM (Kd); Abl-1: 3 nM (Kd); VEGFR-2: 8 nM (Kd); CSF-1R: 9 nM (Kd); EPHA2: 14 nM (Kd); EGFR: 22 nM (Kd); c-Met: 513 nM (Kd); JAK-2: 4700 nM (Kd); MEK-1: 7100 nM (Kd); MEK-2: 8300 nM (Kd)
CEP-32496 Preparation Products And Raw materials
Tag:CEP-32496(1227678-26-3) Related Product Information
PLX4032 Testolactone GDC-0077 AGI6780 CC0651 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine IDO-IN-7 UNC 0631 XL 228 N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea Ethyl 5-oxo-1-phenyl-2-pyrazoline-3-carboxylate 5-(1,1,1-Trifluoro-2-methylpropan-2-yl)isoxazol-3-amine Sorafenib Pazopanib Encorafenib (LGX818) Dabrafenib Regorafenib Plx-4032 (RG7024)